MedPath

PULmonary DAMage after hospitalization for acute COvid-19 (PULDAMCO), an exploratory prospective cohort study

Recruiting
Conditions
COVID-19
Registration Number
NL-OMON23357
Lead Sponsor
Radboudumc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

? Hospital admission for COVID-19
? CT during admission with CO-RADS >=3
? Informed consent

Exclusion Criteria

? Age < 18
? Pregnancy
? Renal failure (MDRD < 30 ml/kg/1,73m^2)
? Allergic reaction to iodine containing intravenous contrast media

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Prevalence of residual lung damage (per type) at 3 and 12 month<br>-Estimated percentage of lung parenchyma affected by various types of diffuse lung damage (e.g., ground glass, consolidation, perfusion abnormalities)<br>-Number of lung segments affected by focal lung damage (e.g., traction bronchiectasis, residual lung emboli)<br>-Predictors of pulmonary damage after acute COVID-19
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath